Charles Sawyers

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening
    Kimberly Brown Dahlman
    Human Oncology and Pathogenesis Program, Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS ONE 7:e34414. 2012
  2. pmc MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors
    Nicola J Clegg
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS ONE 6:e17449. 2011
  3. pmc Something lost--something gained: the ASCI begins its second century
    Charles L Sawyers
    Howard Hughes Medical Institute, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Clin Invest 118:1213-4. 2008
  4. doi request reprint Finding and drugging the vulnerabilities of RAS-dependent cancers
    Charles L Sawyers
    Howard Hughes Medical Institute, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Cell 137:796-8. 2009
  5. pmc Development of a second-generation antiandrogen for treatment of advanced prostate cancer
    Chris Tran
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Science 324:787-90. 2009
  6. ncbi request reprint Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:8253-61. 2005
  7. pmc Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Lancet 375:1437-46. 2010
  8. pmc Targeting the androgen receptor pathway in prostate cancer
    Yu Chen
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Curr Opin Pharmacol 8:440-8. 2008
  9. pmc Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
    Philip A Watson
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 107:16759-65. 2010
  10. ncbi request reprint Targeted cancer therapy
    Charles Sawyers
    Howard Hughes Medical Institute, David Geffen School of Medicine at UCLA, Jonsson Comprehensive Cancer Center, 10833 LeConte Avenue, Los Angeles, California 90095, USA
    Nature 432:294-7. 2004

Research Grants

  1. MOUSE MODELS FOR HUMAN PROSTATE CANCER
    Charles Sawyers; Fiscal Year: 2007
  2. Molecular Biology in Clinical Oncology Workshop
    Charles Sawyers; Fiscal Year: 2007
  3. REGULATION OF THE PTEN GENE IN PROSTATE CANCER
    Charles Sawyers; Fiscal Year: 2001
  4. STEM CELL GENES IN PROSTATE GROWTH AND DIFFERENTIATION
    Charles Sawyers; Fiscal Year: 2001
  5. REGULATION OF THE PTEN GENE IN PROSTATE CANCER
    Charles Sawyers; Fiscal Year: 2000
  6. STEM CELL GENES IN PROSTATE GROWTH AND DIFFERENTIATION
    Charles Sawyers; Fiscal Year: 2000
  7. STEM CELL GENES IN PROSTATE GROWTH AND DIFFERENTIATION
    Charles Sawyers; Fiscal Year: 1999
  8. STEM CELL GENES IN PROSTATE GROWTH AND DIFFERENTIATION
    Charles Sawyers; Fiscal Year: 1999

Collaborators

Detail Information

Publications39

  1. pmc Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening
    Kimberly Brown Dahlman
    Human Oncology and Pathogenesis Program, Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS ONE 7:e34414. 2012
    ..Recovery of hairpins targeting a known prostate cancer pathway validates the utility of shRNA library screening in prostate cancer as a broad strategy to identify new candidate drug targets...
  2. pmc MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors
    Nicola J Clegg
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS ONE 6:e17449. 2011
    ..Since increased MYC expression is an early feature of many human prostate cancers, these data have implications for treatment of human prostate cancers with PI3K-pathway alterations using mTOR inhibitors...
  3. pmc Something lost--something gained: the ASCI begins its second century
    Charles L Sawyers
    Howard Hughes Medical Institute, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Clin Invest 118:1213-4. 2008
    ..Their recollections provide a view of the changes that have occurred in academic medicine in general and for the physician-scientist in particular...
  4. doi request reprint Finding and drugging the vulnerabilities of RAS-dependent cancers
    Charles L Sawyers
    Howard Hughes Medical Institute, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Cell 137:796-8. 2009
    ..Two papers in this issue (Luo et al., 2009; Scholl et al., 2009) could change this landscape by uncovering kinase-specific vulnerabilities in tumors with RAS mutations...
  5. pmc Development of a second-generation antiandrogen for treatment of advanced prostate cancer
    Chris Tran
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Science 324:787-90. 2009
    ..These compounds thus appear to be promising candidates for treatment of advanced prostate cancer...
  6. ncbi request reprint Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:8253-61. 2005
    ..On the basis of this schema, we discuss strategies that are focused on the AR either directly or indirectly, as single agents or in combination, that are in clinical development...
  7. pmc Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Lancet 375:1437-46. 2010
    ..Because growth of castration-resistant prostate cancer is dependent on continued androgen-receptor signalling, we assessed the antitumour activity and safety of MDV3100 in men with this disease...
  8. pmc Targeting the androgen receptor pathway in prostate cancer
    Yu Chen
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Curr Opin Pharmacol 8:440-8. 2008
    ..Many of these strategies are currently being tested in clinical trials in CRPC...
  9. pmc Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
    Philip A Watson
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 107:16759-65. 2010
    ....
  10. ncbi request reprint Targeted cancer therapy
    Charles Sawyers
    Howard Hughes Medical Institute, David Geffen School of Medicine at UCLA, Jonsson Comprehensive Cancer Center, 10833 LeConte Avenue, Los Angeles, California 90095, USA
    Nature 432:294-7. 2004
    ..Recent progress in understanding the molecular changes that underlie cancer development offer the prospect of specifically targeting malfunctioning molecules and pathways to achieve more effective and rational cancer therapy...
  11. ncbi request reprint Opportunities and challenges in the development of kinase inhibitor therapy for cancer
    Charles L Sawyers
    Howard Hughes Medical Institute, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Genes Dev 17:2998-3010. 2003
  12. pmc ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours
    Ping Chi
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Nature 467:849-53. 2010
    ..It also represents a novel mechanism of oncogenic transcription factor activation...
  13. ncbi request reprint Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells
    Maria Y Wang
    Department of Pathology and Laboratory Medicine, Henry E Singleton Brain Tumor Program, Howard Hughes Medical Institute, David Geffen School of Medicine, University of California at Los Angeles, CA 90095 1732, USA
    Cancer Res 66:7864-9. 2006
    ..These studies provide strong rationale for combined mTOR/EGFR kinase inhibitor therapy in glioblastoma patients, particularly those with PTEN-deficient tumors...
  14. pmc Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants
    Brian J Skaggs
    Howard Hughes Medical Institute, University of California, Los Angeles, CA 90095, USA
    Proc Natl Acad Sci U S A 103:19466-71. 2006
    ..Therefore, mutations that confer clinical resistance to kinase inhibitors can substantially alter kinase function and confer novel biological properties that may impact disease progression...
  15. doi request reprint The cancer biomarker problem
    Charles L Sawyers
    Howard Hughes Medical Institute, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USA
    Nature 452:548-52. 2008
    ..One of the main barriers to further progress is identifying the biological indicators, or biomarkers, of cancer that predict who will benefit from a particular targeted therapy...
  16. ncbi request reprint Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680
    Matthew A Young
    Departments of Molecular and Cell Biology and Chemistry, Howard Hughes Medical Institute, The University of California at Berkeley, Berkeley, CA 94720, USA
    Cancer Res 66:1007-14. 2006
    ....
  17. pmc Integrative genomic profiling of human prostate cancer
    Barry S Taylor
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Cancer Cell 18:11-22. 2010
    ..The genomic and clinical outcome data from these patients are now made available as a public resource...
  18. pmc Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis
    Jennifer C King
    Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Nat Genet 41:524-6. 2009
    ..TMPRSS2-ERG-positive human tumors are also enriched for PTEN loss, suggesting cooperation in prostate tumorigenesis...
  19. ncbi request reprint Will mTOR inhibitors make it as cancer drugs?
    Charles L Sawyers
    Howard Hughes Medical Institute, Los Angeles, CA 90095, USA
    Cancer Cell 4:343-8. 2003
  20. ncbi request reprint A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants
    David R Huron
    Department of Medicine, Memorial Sloan Kettering Cancer Center and Program in Pharmacology, New York, New York 10021, USA
    Clin Cancer Res 9:1267-73. 2003
    ..PD166326 is a prototype of a new generation of anti-Bcr-abl compounds with picomolar potency and substantial activity against STI571-resistant mutants...
  21. ncbi request reprint Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line
    Philip A Watson
    Division of Hematology Oncology, Department of Medicine, University of California at Los Angeles, 90095, USA
    Cancer Res 65:11565-71. 2005
    ....
  22. ncbi request reprint Molecular determinants of resistance to antiandrogen therapy
    Charlie D Chen
    Department of Medicine, University of California at Los Angeles, Los Angeles, California 90095, USA
    Nat Med 10:33-9. 2004
    ..These findings provide insight toward the design of new antiandrogens...
  23. pmc The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth
    Ren Jie Jin
    Vanderbilt Prostate Cancer Center and Department of Urologic Surgery, Vanderbilt University Medical Center, A1329 MCN, 1161 21st Avenue South, Nashville, TN 37232 2765, USA
    Cancer Res 68:6762-9. 2008
    ..Thus, the NF-kappaB pathway may be a potential target for therapy against androgen-independent prostate cancer...
  24. pmc A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression
    Pradip K Majumder
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Cell 14:146-55. 2008
    ..These data suggest that a p27(Kip1)-driven checkpoint limits progression of PIN to CaP...
  25. pmc Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma
    Tim F Cloughesy
    Department of Neurology, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America
    PLoS Med 5:e8. 2008
    ..Small, molecularly focused clinical studies offer the promise of the early definition of optimal biologic dose and patient population...
  26. ncbi request reprint TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells
    Sigal Gery
    Division of Hematology Oncology, Cedars Sinai Medical Center, Los Angeles, California, CA 90048, USA
    Oncogene 21:4739-46. 2002
    ....
  27. ncbi request reprint Chromosomal aberrations in prostate cancer xenografts detected by comparative genomic hybridization
    Sari Laitinen
    Laboratory of Cancer Genetics, Institute of Medical Technology, University of Tampere and Tampere University Hospital, Tampere, Finland
    Genes Chromosomes Cancer 35:66-73. 2002
    ..In conclusion, the identified genetic aberrations lay the groundwork for further detailed genetic analyses of these xenografts...
  28. ncbi request reprint Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts
    Ingo K Mellinghoff
    Department of Medicine, School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
    Cancer Res 62:5254-9. 2002
    ..These results suggest that ErbB1/ErbB2 RTKs play an important role in the biology of androgen-independent prostate cancer and provide a rationale for clinical evaluation of inhibitors targeted to this pathway...
  29. ncbi request reprint Whole-body skeletal imaging in mice utilizing microPET: optimization of reproducibility and applications in animal models of bone disease
    Frank Berger
    The Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology University of California School of Medicine, 700 Westwood Blvd, Los Angeles, CA 90095, USA
    Eur J Nucl Med Mol Imaging 29:1225-36. 2002
    ..Morphological imaging with microCAT is useful to display correlative changes in anatomy. Detailed in vivo studies of the murine skeleton in various small animal models of bone diseases should now be possible...
  30. ncbi request reprint MicroPET imaging of prostate cancer in LNCAP-SR39TK-GFP mouse xenografts
    Honghao Yang
    Department of Medicine, Division of Hematology Oncology, UCLA School of Medicine, 10833 LeConte Avenue, Los Angeles, CA 90095, USA
    Prostate 55:39-47. 2003
    ..The aim of this study was to develop models that allow serial, noninvasive imaging of human prostate cancer cells in immunodeficient mice using a dedicated small animal positron emission tomography scanner (microPET)...
  31. ncbi request reprint Myc-driven murine prostate cancer shares molecular features with human prostate tumors
    Katharine Ellwood-Yen
    Department of Medicine, and Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    Cancer Cell 4:223-38. 2003
    ..This approach illustrates how genomic technologies can be applied to mouse cancer models to guide evaluation of human tumor databases...
  32. ncbi request reprint HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability
    Ingo K Mellinghoff
    Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA
    Cancer Cell 6:517-27. 2004
    ..Surprisingly, the downstream signaling pathway responsible for these effects appears to involve kinases other than Akt. These data suggest that the HER2/ERBB3 pathway is a critical target in hormone-refractory prostate cancer...
  33. ncbi request reprint Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer
    George V Thomas
    Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095, USA
    Clin Cancer Res 10:8351-6. 2004
    ..Prostate cancers also present unique organ-specific challenges, in that tumors are heterogeneous and diagnostic tissue is extremely limited...
  34. ncbi request reprint Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta-catenin complexes
    Jung Hwa Kim
    Department of Biological Sciences, College of Natural Sciences, Seoul National University, Seoul 151 742, South Korea
    Nature 434:921-6. 2005
    ....
  35. ncbi request reprint Amplification and overexpression of prosaposin in prostate cancer
    Shahriar Koochekpour
    Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
    Genes Chromosomes Cancer 44:351-64. 2005
    ....
  36. pmc Ligand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells
    Sung Hee Baek
    Department of Biological Sciences, Research Center for Functional Cellulomics, Seoul National University, South Korea
    Proc Natl Acad Sci U S A 103:3100-5. 2006
    ....
  37. ncbi request reprint Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development
    Jing Jiao
    Department of Molecular and Medical Pharmacology, University of California at Los Angeles, Los Angeles, California 90095 1735, USA
    Cancer Res 67:6083-91. 2007
    ..These cell lines will serve as useful tools for understanding signaling pathways controlled by PTEN and elucidating the molecular mechanisms involved in hormone refractory prostate cancer formation...
  38. pmc NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer
    Charlie D Chen
    Division of Hematology Oncology, Department of Medicine, University of California at Los Angeles, Los Angeles, California 90095 1678, USA
    Mol Cell Biol 22:2862-70. 2002
    ..These results suggest a role of NF-kappa B in prostate cancer progression...

Research Grants11

  1. MOUSE MODELS FOR HUMAN PROSTATE CANCER
    Charles Sawyers; Fiscal Year: 2007
    ..abstract_text> ..
  2. Molecular Biology in Clinical Oncology Workshop
    Charles Sawyers; Fiscal Year: 2007
    ..Professional evaluation of the program is provided by Dr. Rebecca Lipner and Mr. Louis Grosso of the American Board of Internal Medicine. ..
  3. REGULATION OF THE PTEN GENE IN PROSTATE CANCER
    Charles Sawyers; Fiscal Year: 2001
    ..Together, these experiments will define a novel mode of PTEN regulation in human cancers. ..
  4. STEM CELL GENES IN PROSTATE GROWTH AND DIFFERENTIATION
    Charles Sawyers; Fiscal Year: 2001
    ..These studies will enhance our understanding of the potential role of prostatic stem cell population in the normal and abnormal growth of the prostate that characterizes benign prostatic hypertrophy. ..
  5. REGULATION OF THE PTEN GENE IN PROSTATE CANCER
    Charles Sawyers; Fiscal Year: 2000
    ..Together, these experiments will define a novel mode of PTEN regulation in human cancers. ..
  6. STEM CELL GENES IN PROSTATE GROWTH AND DIFFERENTIATION
    Charles Sawyers; Fiscal Year: 2000
    ..These studies will enhance our understanding of the potential role of prostatic stem cell population in the normal and abnormal growth of the prostate that characterizes benign prostatic hypertrophy. ..
  7. STEM CELL GENES IN PROSTATE GROWTH AND DIFFERENTIATION
    Charles Sawyers; Fiscal Year: 1999
    ..These studies will enhance our understanding of the potential role of prostatic stem cell population in the normal and abnormal growth of the prostate that characterizes benign prostatic hypertrophy. ..
  8. STEM CELL GENES IN PROSTATE GROWTH AND DIFFERENTIATION
    Charles Sawyers; Fiscal Year: 1999
    ..These studies will enhance our understanding of the potential role of prostatic stem cell population in the normal and abnormal growth of the prostate that characterizes benign prostatic hypertrophy. ..